Analysis of 660 Reddit posts reveals real-world patient narratives about semaglutide 2.4 mg for weight loss, including benefits and challenges.
660 postsReddit posts analyzed from r/WegovyWeightLoss capturing unfiltered patient narratives
What the researchers found
Qualitative analysis of 660 Reddit posts provides rich patient narratives about real-world semaglutide 2.4 mg experiences during a period of high demand and shortages.
Why it matters
Clinical trials capture efficacy and side effects, but patient forums reveal the full lived experience — access struggles, emotional journey, and real-world challenges.
The numbers in context
1,000 posts screened from r/WegovyWeightLoss (Oct 2022-Oct 2023). 660 included. 7 themes: efficacy (29.4%), psychosocial impact (22.8%), side effects, access, lifestyle, comparisons, stigma.
How the study worked
Retrospective qualitative analysis of 660 Reddit posts from r/WegovyWeightLoss using collaborative codebook development and qualitative coding.
Who was studied
Reddit users discussing Wegovy (semaglutide 2.4 mg)
What this study cannot tell us
Reddit users may not represent all semaglutide patients — skews younger and more tech-savvy. Self-reported data without verification.
How to read the evidence
Qualitative social media analysis — captures authentic patient voice but cannot establish efficacy or generalize to all patients.
When this study was published
Published in 2025, covering a critical period of Wegovy adoption and supply challenges.
The bigger picture
Social media analysis captures patient experiences that traditional research misses, informing more patient-centered care and policy discussions around anti-obesity drugs.
Questions still open
- How do Reddit experiences compare to clinical trial outcomes?
- Do supply shortages affect treatment adherence and outcomes?
Common questions
What do real patients say about Wegovy?
Is Reddit a reliable source for drug information?
Read the original research
A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss.
Obesity science & practice, 11(4), e70085
Citation
Plenn, Eion; Amin, Dylan; Henry, Jonathan; Leavitt, Gabrielle; Walker, Jason; Soleymani, Taraneh. (2025). A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss.. Obesity science & practice, 11(4), e70085. https://doi.org/10.1002/osp4.70085